Interferon-alpha, a biologic drug, can benefit patients with blood cancers called myeloproliferative neoplasms by changing mutant blood stem cells into shorter-lived white blood cells, according to a study by investigators at Weill Cornell Medicine. The research showed that the therapy redirects the development path of abnormal cells, offering a new avenue for treatment.
Myeloproliferative neoplasms arise when DNA mutations in blood-forming stem cells cause an overproduction of particular blood lineages. For example, megakaryocyte cells, which normally generate platelets, may proliferate excessively, leading to raised platelet counts and associated complications.
How Interferon-Alpha Works
Interferon-alpha often helps patients by reducing these imbalances and by depleting the pool of mutant blood-forming cells. In the study published in Nature Genetics, researchers used high-resolution single-cell profiling tools to trace how the drug reshapes cellular behavior at the molecular level.
“These findings provide strategies for new ways to manage these and potentially other blood cancers,” said study senior author Dr. Anna Nam, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine. She emphasized that the insights could guide the design of more precise interventions.
Blood stem cells reside in the bone marrow and give rise to all major blood components, including oxygen-carrying red cells, platelet-producing megakaryocytes, and immune-system white cells. Their ability to differentiate into diverse lineages makes them a focal point for therapeutic manipulation.
Single-Cell Profiling Methods
Dr. Nam and her collaborators applied single-cell profiling to capture gene-activity signatures, surface-protein patterns, and other traits of thousands of individual cells taken from patients diagnosed with essential thrombocythemia, a form of myeloproliferative neoplasm marked by high platelet numbers.
The team examined cells before treatment and after exposure to interferon-alpha, discovering that the drug can trigger an emergency-infection-like response. This reaction pushes blood-forming cells to accelerate their maturation into infection-fighting neutrophils.
Neutrophils have a brief lifespan, so their rapid production creates a temporary surge of short-lived white cells. Over time, this inflammatory burst exhausts the reservoir of blood-forming cells, gradually lowering the number of abnormal clones.
Mutant stem cells proved more vulnerable to this process than their normal counterparts in patients who responded to the therapy. The heightened sensitivity accelerates the removal of disease-driving cells while sparing healthy ones.
Leave a Reply